Gyre Therapeutics, Inc. (GYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.86+6.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GYRE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -57.1% |
| Our one-year growth estimate | diamond | 14.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 71.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GYRE — earnings miss
Dated 2026-08-07
and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Good results can show ETUARY works well for a new use. This can boost its market value.
Supportive ifPositive results come from the Phase 2/3 trial for ETUARY in lung injury from radiation.
Worry ifNegative results or delays in the trial for ETUARY in this use are announced.
Why it matters: Approval would help Gyre's pipeline. This could boost market confidence a lot.
Supportive ifOfficial announcement of NDA approval for F351 by China's NMPA.
Worry ifIf NMPA rejects or delays approval, it could hurt investor feelings.
Why it matters: Completing the acquisition is key for Gyre's growth strategy. It could boost future revenue.
Supportive ifAn official announcement says Cullgen Inc. is now part of Gyre's operations.
Worry ifDelays or problems in buying slow down integration.
Why it matters: Approval would show Gyre's strong clinical data. It would help future revenue growth.
Supportive ifChina's CDE approves F351 to treat liver fibrosis related to CHB.
Worry ifCDE denies approval or delays the decision past the expected time.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$216 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $526 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,732 loss on $10,000 · 37.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If sector growth speeds up, it could benefit Gyre. This may improve its performance outlook.
Supportive ifSector revenue growth is speeding up to 10% or more.
Worry ifSector revenue growth keeps slowing down to below 5%.
Why it matters: Filing the IND is key for advancing F351's development in the U.S. market.
Supportive ifGyre files the IND for F351 by the end of 2026.
Worry ifThe IND filing for F351 is delayed beyond 2026.
Why it matters: Starting the Phase 2 trial for F351 would signal progress in Gyre's key pipeline asset.
Supportive ifAnnouncement of the initiation of the Phase 2 trial for F351 in the U.S.
Worry ifDelay in starting the Phase 2 trial beyond 2026 would indicate potential setbacks.
Why it matters: Meeting this revenue target would confirm Gyre's ability to achieve its full-year guidance. It shows strong sales momentum.
Supportive ifQ3 revenue reported at or above $33.4 million, indicating strong growth.
Worry ifQ3 revenue falls below $30 million, suggesting challenges in sales growth.
Why it matters: Finishing this trial is key for F351's approval and future earnings.
Supportive ifAnnouncement that the final patient has completed the Phase 3 trial for F351.
Worry ifDelay in trial completion or negative results from the trial.
Why it matters: Good integration will improve Gyre's pipeline and operations. This will affect future growth.
Watch forManagement will share news about how the integration is going. They will also talk about pipeline growth.
Also watch forThere are no news about problems or delays with the integration.